Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 entities : Cytokinetics, incorporated save search
Cytokinetics Announces Start of SEQUOIA-HCM, a Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Published: 2022-02-23 (Crawled : 13:30) - biospace.com/
CYTK | $66.82 1.91% 1.78% 810K
|
Health Technology
|
| O: 0.0%
H: 1.25%
C: -6.95%
cardio trial star phase 3
Cytokinetics Announces Start of COURAGE-ALS, a Phase 3 Clinical Trial of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis
Published: 2021-08-02 (Crawled : 12:00) - globenewswire.com
CYTK | $66.82 1.91% 1.78% 810K
|
Health Technology
|
| O: 2.52%
H: 1.57%
C: -3.03%
sclerosis phase 3 trial als
Cytokinetics Announces Completion of Enrollment in METEORIC-HF, The Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure With Reduced Ejection Fraction
Published: 2021-06-15 (Crawled : 12:00) - globenewswire.com
CYTK | $66.82 1.91% 1.78% 810K
|
Health Technology
|
| O: -0.23%
H: 4.68%
C: 2.2%
heart phase 3 trial enroll
Cytokinetics Announces Data and Trial Design Presented at the International Symposium on ALS/MNDAdditional Data from FORTITUDE-ALS Support Rationale and Design for COURAGE-ALS, A Planned Phase 3 Clinical Trial of Reldesemtiv in Patients with ALS
Published: 2020-12-14 (Crawled : 15:00) - biospace.com/
CYTK | $66.82 1.91% 1.78% 810K
|
Health Technology
|
| O: -1.62%
H: 8.25%
C: 6.15%
phase 3 trial als symposium designation
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3772271
Published: 2020-09-23 (Crawled : 09:33) - globenewswire.com
CYTK | $66.82 1.91% 1.78% 810K
|
Health Technology
|
| O: -1.36%
H: 6.7%
C: 3.79%
phase 3 phase 1 phase 2
Amgen, Cytokinetics and Servier Announce Topline Results From GALACTIC-HF, a Phase 3 Trial of Omecamtiv Mecarbil in Patients With Heart Failure
Published: 2020-10-08 (Crawled : 09:33) - globenewswire.com
CYTK | $66.82 1.91% 1.78% 810K
|
Health Technology
|
| O: -36.9%
H: 1.6%
C: -8.31%
results heart phase 3 trial topline
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
RILY | $29.75 36.97% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.